DALBAVANCIN

Generic: DALBAVANCIN

Meitheal Pharmaceuticals IncManufacturer
INTRAVENOUSRoute
DALBAVANCIN HYDROCHLORIDEActive Substance
2025-11-26Original Approval

DALBAVANCIN is FDA application ANDA218929, sponsored by EMERGE BIOSCIENCE. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Top Reported Reactions

1
OFF LABEL USE
45 reports
2
DRUG INEFFECTIVE
38 reports
3
ACUTE KIDNEY INJURY
35 reports
4
PYREXIA
34 reports
5
VOMITING
34 reports
6
DIARRHOEA
19 reports
7
INFUSION RELATED REACTION
19 reports
8
MALAISE
18 reports
9
DECREASED APPETITE
17 reports
10
ERYTHEMA
16 reports